Yepes, Andres F. published the artcileDiscovery of novel donepezil-M30D hybrids with neuroprotective properties for Alzheimers disease treatment, Category: isoquinoline, the main research area is Alzheimers disease mol hybrid neuroprotective pharmacokinetics.
Herein, we designed and synthesized a novel family of mol. hybrids based on the pharmacophoric combination strategy, joining key pharmacophoric features from donepezil and M30D with neuroprotector effects, aiming at obtaining promising medicinal scaffolds for AD treatment. The neuroprotective profile of novel donepezil-M30D hybrids was evaluated by combining the glutamate excitotoxicity assay in neural cells, cytosolic calcium imaging, and through neuron/astrocyte coculture after glutamate exposure. Our results revealed that novel hybrids 6b, 6d, 6g and 6h highlighted for their neuroprotector potency against glutamate-induced excitotoxicity. Specifically, 6d treatment protected cortical neurons treated with an excitotoxic glutamate stimuli recovering calcium dynamics. Likewise, treatment with the 6d hybrid prevented neuronal death and astroglia reactivity in a coculture model of glutamate excitotoxity. Computational simulations and exptl. anal. would suggest that the neuroprotective effects of active compounds could be related to blockade of NMDA channel pore. Optimal pharmacokinetics properties were founded for the most active hybrids involving a remarkable in vitro human plasma stability, as well as suitable in silico ADME profile. In summary, hybridization of key pharmacophoric features from M30D and donepezil provide biol. active compounds that could be used as promising scaffolds for the design of future plasma-stable neuroprotective agents to fight Alzheimers disease (AD).
Medicinal Chemistry Research published new progress about Affinity. 86-51-1 belongs to class isoquinoline, name is 2,3-Dimethoxybenzaldehyde, and the molecular formula is C9H10O3, Category: isoquinoline.
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem